CRISPR Therapeutics (CRSP) 10-Q2024 Q1 Quarterly report

Filed: 8 May 24, 4:20pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: advantage, altering, Arabia, Bahrain, batch, blood, Britain, called, CASGEVY, chronic, closing, consumable, contemplated, Counsel, culminating, cure, dedicated, deeply, defective, degree, depleting, depletion, device, erythroid, Europe, exhibit, fetal, Finally, GMP, goal, Great, group, half, hemoglobin, higher, hypoimmune, immunosuppression, implanted, institutional, Jim, Kasinger, landmark, lipid, lipoprotein, manner, older, oncology, people, permitted, persistence, pharmacology, population, power, produce, produced, producing, professional, progenitor, proven, red, safely, Secretary, serve, shown, spanning, speed, stamp, strong, unencapsulated, unparalleled, wholly, word

Removed: accessibility, adapted, addback, age, amenable, bacteria, basket, borne, Canada, carcinoma, Charpentier, clear, cleared, Cluster, concept, concurrent, CTCL, CVD, damage, delivering, Differentiation, dose, Dr, effort, elucidating, EMA, Emmanuelle, EU, evasion, expanded, extrahepatic, fate, found, gained, genetically, Health, Healthcare, healthy, immune, improve, independent, initially, Innovation, innovative, investigating, Kingdom, launched, lost, lymphoma, mechanism, MHRA, mutually, naturally, occurring, organ, originally, Passport, Pathway, pediatric, promote, published, range, reached, renal, replace, suppression, Syndrome, system, tissue, work

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CRSP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of CRISPR Therapeutics AG (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

/s/ Samarth Kulkarni

Samarth Kulkarni

Chief Executive Officer

(Principal Executive Officer)

May 8, 2024

/s/ Raju Prasad

Raju Prasad

Chief Financial Officer

(Principal Financial and Accounting Officer)

May 8, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.